Price T Rowe Associates Inc. MD Has $550.84 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Price T Rowe Associates Inc. MD boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,685,753 shares of the biopharmaceutical company’s stock after acquiring an additional 201,784 shares during the quarter. Price T Rowe Associates Inc. MD owned 2.91% of Alnylam Pharmaceuticals worth $550,837,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $30,000. GAMMA Investing LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $52,000. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $0.01 during midday trading on Monday, hitting $234.85. 56,820 shares of the company traded hands, compared to its average volume of 876,563. The company’s 50-day moving average is $198.99 and its 200 day moving average is $172.41. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same period in the previous year, the business earned ($1.40) EPS. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Royal Bank of Canada lifted their price target on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, June 25th. UBS Group increased their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Chardan Capital reaffirmed a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 25th. Finally, StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.73.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold a total of 74,450 shares of company stock worth $15,287,984 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.